

# Qi Cao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4856608/publications.pdf>

Version: 2024-02-01

74  
papers

12,789  
citations

101384

36  
h-index

74018

75  
g-index

77  
all docs

77  
docs citations

77  
times ranked

17676  
citing authors

#	ARTICLE	IF	CITATIONS
1	Methylation-dependent and -independent roles of EZH2 synergize in CDCA8 activation in prostate cancer. <i>Oncogene</i> , 2022, 41, 1610-1621.	2.6	6
2	MACMIC Reveals A Dual Role of CTCF in Epigenetic Regulation of Cell Identity Genes. <i>Genomics, Proteomics and Bioinformatics</i> , 2021, 19, 140-153.	3.0	4
3	Androgen Receptor-Related Non-coding RNAs in Prostate Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 660853.	1.8	20
4	A PRC2-independent function for EZH2 in regulating rRNA 2â€²-O methylation and IRES-dependent translation. <i>Nature Cell Biology</i> , 2021, 23, 341-354.	4.6	54
5	A pan-cancer transcriptome analysis of exon splicing identifies novel cancer driver genes and neopeptides. <i>Molecular Cell</i> , 2021, 81, 2246-2260.e12.	4.5	35
6	Robot-assisted laparoscopic retroperitoneal leiomyosarcoma resection with inferior vena cava graft replacement: a case report. <i>Translational Andrology and Urology</i> , 2021, 10, 2133-2139.	0.6	4
7	High SAA1 Expression Predicts Advanced Tumors in Renal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 649761.	1.3	13
8	LncGSEA: a versatile tool to infer lncRNA associated pathways from large-scale cancer transcriptome sequencing data. <i>BMC Genomics</i> , 2021, 22, 574.	1.2	2
9	Pharmacological Inhibition of Core Regulatory Circuitry Liquidâ€²liquid Phase Separation Suppresses Metastasis and Chemoresistance in Osteosarcoma. <i>Advanced Science</i> , 2021, 8, e2101895.	5.6	27
10	Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression. <i>Oncogene</i> , 2020, 39, 6265-6285.	2.6	52
11	Long noncoding RNA SNHG12 indicates the prognosis of prostate cancer and accelerates tumorigenesis via sponging miRâ€²133b. <i>Journal of Cellular Physiology</i> , 2020, 235, 1235-1246.	2.0	39
12	BMI1 is directly regulated by androgen receptor to promote castration-resistance in prostate cancer. <i>Oncogene</i> , 2020, 39, 17-29.	2.6	22
13	Editorial: Response and Resistance in Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 607298.	1.3	1
14	Antihistamine Drug Ebastine Inhibits Cancer Growth by Targeting Polycomb Group Protein EZH2. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2023-2033.	1.9	15
15	Broad genic repression domains signify enhanced silencing of oncogenes. <i>Nature Communications</i> , 2020, 11, 5560.	5.8	10
16	Machine learning uncovers cell identity regulator by histone code. <i>Nature Communications</i> , 2020, 11, 2696.	5.8	25
17	The Identification of Key Gene Expression Signature and Biological Pathways in Metastatic Renal Cell Carcinoma. <i>Journal of Cancer</i> , 2020, 11, 1712-1726.	1.2	5
18	IMPDH1/YB-1 Positive Feedback Loop Assembles Cytophidia and Represents a Therapeutic Target in Metastatic Tumors. <i>Molecular Therapy</i> , 2020, 28, 1299-1313.	3.7	20

#	ARTICLE	IF	CITATIONS
19	Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1516-1528.	3.2	34
20	TADsplimer reveals splits and mergers of topologically associating domains for epigenetic regulation of transcription. <i>Genome Biology</i> , 2020, 21, 84.	3.8	6
21	The Identification of Key Gene Expression Signature in Prostate Cancer. <i>Critical Reviews in Eukaryotic Gene Expression</i> , 2020, 30, 153-168.	0.4	3
22	ISG20 serves as a potential biomarker and drives tumor progression in clear cell renal cell carcinoma. <i>Aging</i> , 2020, 12, 1808-1827.	1.4	25
23	LINC00160 mediates sunitinib resistance in renal cell carcinoma via SAA1 that is implicated in STAT3 activation and compound transportation. <i>Aging</i> , 2020, 12, 17459-17479.	1.4	10
24	Impact of inflammation and immunotherapy in renal cell carcinoma (Review). <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	19
25	CYP17 inhibitors improve the prognosis of metastatic castration-resistant prostate cancer patients: A meta-analysis of published trials. <i>Journal of Cancer Research and Therapeutics</i> , 2020, 16, 990.	0.3	4
26	Identification of CXCL13 as a potential biomarker in clear cell renal cell carcinoma via comprehensive bioinformatics analysis. <i>Biomedicine and Pharmacotherapy</i> , 2019, 118, 109264.	2.5	30
27	RAC2 acts as a prognostic biomarker and promotes the progression of clear cell renal cell carcinoma. <i>International Journal of Oncology</i> , 2019, 55, 645-656.	1.4	20
28	Role of Autophagy in Renal Cancer. <i>Journal of Cancer</i> , 2019, 10, 2501-2509.	1.2	40
29	Melatonin/PGC1A/UCP1 promotes tumor slimming and represses tumor progression by initiating autophagy and lipid browning. <i>Journal of Pineal Research</i> , 2019, 67, e12607.	3.4	57
30	N6-Methyladenosine Modulates Nonsense-Mediated mRNA Decay in Human Glioblastoma. <i>Cancer Research</i> , 2019, 79, 5785-5798.	0.4	181
31	The Identification of Potential Biomarkers and Biological Pathways in Prostate Cancer. <i>Journal of Cancer</i> , 2019, 10, 1398-1408.	1.2	24
32	High expression of TAZ serves as a novel prognostic biomarker and drives cancer progression in renal cancer. <i>Experimental Cell Research</i> , 2019, 376, 181-191.	1.2	6
33	LXR $\pm$ promotes cell metastasis by regulating the NLRP3 inflammasome in renal cell carcinoma. <i>Cell Death and Disease</i> , 2019, 10, 159.	2.7	30
34	Polycomb group proteins EZH2 and EED directly regulate androgen receptor in advanced prostate cancer. <i>International Journal of Cancer</i> , 2019, 145, 415-426.	2.3	51
35	The screening of pivotal gene expression signatures and biomarkers in renal carcinoma. <i>Journal of Cancer</i> , 2019, 10, 6384-6394.	1.2	3
36	B lymphoma Moloney murine leukemia virus insertion region 1: An oncogenic mediator in prostate cancer. <i>Asian Journal of Andrology</i> , 2019, 21, 224.	0.8	8

#	ARTICLE	IF	CITATIONS
37	BMI1 regulates androgen receptor in prostate cancer independently of the polycomb repressive complex 1. <i>Nature Communications</i> , 2018, 9, 500.	5.8	65
38	Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator. <i>Cell Reports</i> , 2018, 25, 2808-2820.e4.	2.9	201
39	RCAN1.4 acts as a suppressor of cancer progression and sunitinib resistance in clear cell renal cell carcinoma. <i>Experimental Cell Research</i> , 2018, 372, 118-128.	1.2	14
40	Overexpression of PLIN2 is a prognostic marker and attenuates tumor progression in clear cell renal cell carcinoma. <i>International Journal of Oncology</i> , 2018, 53, 137-147.	1.4	49
41	PLIN3 is up-regulated and correlates with poor prognosis in clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 343.e9-343.e19.	0.8	27
42	Calpain and AR-V7: Two potential therapeutic targets to overcome acquired docetaxel resistance in castration-resistant prostate cancer cells. <i>Oncology Reports</i> , 2017, 37, 3651-3659.	1.2	4
43	Enhanced expression of caveolin-1 possesses diagnostic and prognostic value and promotes cell migration, invasion and sunitinib resistance in the clear cell renal cell carcinoma. <i>Experimental Cell Research</i> , 2017, 358, 269-278.	1.2	30
44	Potential New Therapies for Pediatric Diffuse Intrinsic Pontine Glioma. <i>Frontiers in Pharmacology</i> , 2017, 8, 495.	1.6	48
45	The Long Non-Coding RNA PCAT-1 Promotes Prostate Cancer Cell Proliferation through cMyc. <i>Neoplasia</i> , 2014, 16, 900-908.	2.3	216
46	PCAT-1, a Long Noncoding RNA, Regulates BRCA2 and Controls Homologous Recombination in Cancer. <i>Cancer Research</i> , 2014, 74, 1651-1660.	0.4	237
47	The central role of EED in the orchestration of polycomb group complexes. <i>Nature Communications</i> , 2014, 5, 3127.	5.8	130
48	The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. <i>Nature Genetics</i> , 2013, 45, 1392-1398.	9.4	601
49	Characterization of the EZH2-MMSET Histone Methyltransferase Regulatory Axis in Cancer. <i>Molecular Cell</i> , 2013, 49, 80-93.	4.5	130
50	Role of Transcriptional Corepressor CtBP1 in Prostate Cancer Progression. <i>Neoplasia</i> , 2012, 14, 905-IN8.	2.3	59
51	Role of dutasteride in preclinical ETS fusion-positive prostate cancer models. <i>Prostate</i> , 2012, 72, 1542-1549.	1.2	13
52	Therapeutic Targeting of SPINK1-Positive Prostate Cancer. <i>Science Translational Medicine</i> , 2011, 3, 72ra17.	5.8	140
53	Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. <i>Nature Biotechnology</i> , 2011, 29, 742-749.	9.4	950
54	Targeting of microRNA-142-3p in dendritic cells regulates endotoxin-induced mortality. <i>Blood</i> , 2011, 117, 6172-6183.	0.6	132

#	ARTICLE	IF	CITATIONS
55	Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer. <i>Cancer Cell</i> , 2011, 19, 664-678.	7.7	397
56	Coordinated Regulation of Polycomb Group Complexes through microRNAs in Cancer. <i>Cancer Cell</i> , 2011, 20, 187-199.	7.7	191
57	TMPRSS2-ERG-Mediated Feed-Forward Regulation of Wild-Type ERG in Human Prostate Cancers. <i>Cancer Research</i> , 2011, 71, 5387-5392.	0.4	42
58	Characterization of KRAS Rearrangements in Metastatic Prostate Cancer. <i>Cancer Discovery</i> , 2011, 1, 35-43.	7.7	91
59	Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in Urine after Digital Rectal Examination Fails as a Marker in Prostate Cancer Detection and Identification of Aggressive Tumours. <i>Eur Urol</i> 2010;58:12-8. <i>European Urology</i> , 2010, 58, e29-e30.	0.9	17
60	An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-ERG Gene Fusions in Prostate Cancer Progression. <i>Cancer Cell</i> , 2010, 17, 443-454.	7.7	743
61	Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. <i>Nature Medicine</i> , 2010, 16, 793-798.	15.2	436
62	AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 10284-10289.	3.3	140
63	Tomlins et al. reply. <i>Nature</i> , 2009, 457, E2-E3.	13.7	6
64	Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. <i>Nature</i> , 2009, 457, 910-914.	13.7	1,944
65	An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. <i>Nature Biotechnology</i> , 2009, 27, 1005-1011.	9.4	69
66	The Role of SPINK1 in ETS Rearrangement-Negative Prostate Cancers. <i>Cancer Cell</i> , 2008, 13, 519-528.	7.7	303
67	Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer. <i>Neoplasia</i> , 2008, 10, 177-IN9.	2.3	608
68	Golgi Protein GOLM1 Is a Tissue and Urine Biomarker of Prostate Cancer. <i>Neoplasia</i> , 2008, 10, 1285-IN35.	2.3	89
69	Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer. <i>Science</i> , 2008, 322, 1695-1699.	6.0	995
70	Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 Gene Fusions in Prostate Cancer. <i>Cancer Research</i> , 2008, 68, 73-80.	0.4	244
71	Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. <i>Nature</i> , 2007, 448, 595-599.	13.7	743
72	Integrative Genomics Analysis Reveals Silencing of $\beta$ -Adrenergic Signaling by Polycomb in Prostate Cancer. <i>Cancer Cell</i> , 2007, 12, 419-431.	7.7	204

#	ARTICLE	IF	CITATIONS
73	The Polycomb Group Protein EZH2 Impairs DNA Repair in Breast Epithelial Cells. <i>Neoplasia</i> , 2005, 7, 1011-1019.	2.3	86
74	EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 11606-11611.	3.3	1,482